natgillin/translations-raw huggingface dataset:
Following oral administration of [3-H]-ospemifene, approximately 75% and 7% of the dose was excreted in faeces and urine respectively.
Po peroralni uporabi [3-H]-ospemifena so 75% odmerka izolirali iz blata in 7% odmerka iz urina.
Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of sitagliptin was 8.52 M•hr, Cmax was 950 nM.
Po peroralni uporabi 100 mg odmerka pri zdravih osebah se je sitagliptin hitro absorbiral; največje koncentracije v plazmi (mediana vrednost Tmax) so se pojavile v 1 do 4 urah po odmerku, povprečna vrednost AUC sitagliptina v plazmi je bila 8,52 M•ur, vrednost Cmax je bila 950 nM.
Following oral administration of a 5 mg radioactive dose of axitinib, 30-60% of the radioactivity was recovered in faeces and 23% of the radioactivity was recovered in urine.
Po peroralnem dajanju 5 mg radioaktivnega odmerka aksitiniba so 30 do 60 % radioaktivnosti ugotovili v blatu, 23 % radioaktivnosti pa so ugotovili v urinu.
Following oral administration of a fixed combination tablet of aliskiren, amlodipine and hydrochlorothiazide, peak concentrations were achieved for aliskiren within 1-2 hours, for amlodipine within 8 hours and for hydrochlorothiazide within 2-3 hours.
Po peroralnem odmerjanju že pripravljene kombinacije tablet aliskirena, amlodipina in hidroklorotiazida doseže aliskiren najvišjo koncentracijo v 1-2 urah, amlodipin v 8 urah in hidroklorotiazid v 2-3 urah.
Following oral administration of a single 30 mg dose, ulipristal acetate is rapidly absorbed, with a peak plasma concentration of 176 ± 89 ng/ml occurring approximately 1 hour (0.5-2.0 h) after ingestion, and with an AUC0-∞ of 556 ± 260 ng.h/ml.
Po enkratnem 30-miligramskem peroralnem odmerku se ulipristalacetat hitro absorbira; najvišja plazemska koncentracija 176 ± 89 ng/ml se pojavi približno 1 uro (0,5–2,0 ure) po zaužitju zdravila, AUC0-∞ pa je 556 ± 260 ng.h/ml.
Following oral administration of a single 40 mg dose of EMEND in the fasted state, the AUC0- (mean ± SD) was 8.0 ± 2.1 µg  h/mL and the Cmax was 0.7 ± 0.24 µg/mL.
Po peroralnem dajanju enkratnega 40 mg odmerka zdravila EMEND na tešče je bila AUC0- (povprečje ± SD) 8,0 ± 2,1 µgh/ml, Cmax pa 0,7 ± 0,24 µg/ml.
Following oral administration of a single dose of ritonavir-boosted [14C]elvitegravir, elvitegravir was the predominant species in plasma, representing approximately 94% and 61% of the circulating radioactivity at 32 and 48 hours, respectively.
Po peroralnem dajanju enega odmerka z ritonavirjem ojačanega [14C]elvitegravirja je bil elvitegravir prevladujoča vrsta v plazmi in je po 32 urah predstavljal približno 94 % in po 48 urah približno 61 % cirkulirajoče radioaktivnosti.
Following oral administration of amlodipine/valsartan, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Po peroralni uporabi amlodipina/valsartana doseže valsartan največjo koncentracijo v plazmi v 3 urah, amlodipin pa v 6 do 8 urah.
Following oral administration of C-14 labelled gefitinib to lactating rats 14 days post partum, concentrations of radioactivity in milk were 11-19 fold higher than in blood.
Po peroralni uporabi s C-14 označenega gefitiniba pri doječih podganah 14 dni po skotitvi je bila koncentracija radioaktivnosti v mleku od 11- do 19-krat večja kot v krvi.
Following oral administration of cabozantinib, peak cabozantinib plasma concentrations are reached at 2 to 3 hours post-dose.
Po peroralni uporabi kabozantiniba so najvišje koncentracije kabozantiniba v plazmi dosežene 2 do 3 ure po odmerku.
Following oral administration of Copalia, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Po peroralni uporabi zdravila Copalia doseže valsartan največjo koncentracijo v plazmi v 3 urah, amlodipin pa v 6 do 8 urah.
Following oral administration of CRESEMBA in healthy subjects, the active moiety isavuconazole is absorbed and reaches maximum plasma concentrations (Cmax) approximately 2–3 hours after single and multiple dosing (see Table 3).
Po peroralni uporabi zdravila CRESEMBA pri zdravih preiskovancih se aktivna spojina izavukonazol absorbira in doseţe največje koncentracije v plazmi (Cmax) pribliţno 2–3 ure po enkratnem in večkratnem odmerjanju (glejte Preglednico 3).
Following oral administration of Dafiro, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Po peroralni uporabi zdravila Dafiro doseže valsartan največjo koncentracijo v plazmi v 3 urah, amlodipin pa v 6 do 8 urah.
Following oral administration of Eviplera with food emtricitabine is rapidly and extensively absorbed with maximum plasma concentrations occurring within 2.5 hours post dose.
Po peroralnem vnosu zdravila Eviplera s hrano se emtricitabin hitro in znatno absorbira, pri čemer so koncentracije v plazmi najvišje 2,5 ure po odmerku.
Following oral administration of Exforge, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Po peroralni uporabi zdravila Exforge doseže valsartan največjo koncentracijo v plazmi v 3 urah, amlodipin pa v 6 do 8 urah.
Following oral administration of Ifirmacombi, the absolute oral bioavailability is 60- 80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Po peroralnem jemanju zdravila Ifirmacombi je biološka uporabnost irbesartana približno 60- do 80-odstotna, hidroklorotiazida pa 50- do 80-odstotna.
Following oral administration of pimobendan alone the absolute bioavailability of the active ingredient is 60–63%.
Po peroralni uporabi samega pimobendana je absolutna biološka uporabnost zdravilne učinkovine 60 - 63 %.
Following oral administration of ritonavir-boosted [14C]elvitegravir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary elimination of elvitegravir; 6.7% of the administered dose was recovered in urine as metabolites.
Po peroralni uporabi z ritonavirjem ojačanega [14C]elvitegravirja so 94,8 % odmerka izolirali iz blata, kar je v skladu s hepatobiliarnim izločanjem elvitegravirja; 6,7 % danega odmerka so izolirali iz urina v obliki presnovkov.
Following oral administration of Stribild with food in HIV-1 infected subjects, peak plasma concentrations were observed 4 hours post-dose for elvitegravir, 3 hours post-dose for cobicistat, 3 hours post-dose for emtricitabine, and 2 hours for tenofovir following the rapid conversion of tenofovir disoproxil fumarate.
Po peroralnem dajanju zdravila Stribild s hrano osebam, okuženim z virusom HIV-1, so najvišje plazemske koncentracije opazili 4 ure po odmerku za elvitegravir, 3 ure po odmerku za kobicistat, 3 ure po odmerku za emtricitabin in 2 uri po odmerku za tenofovir po hitri konverziji dizoproksiltenofovirijevega fumarata.
Following oral administration of tenofovir disoproxil fumarate to HIV infected patients, tenofovir disoproxil fumarate is rapidly absorbed and converted to tenofovir.
Po peroralnem dajanju dizoproksiltenofovirijevega fumarata bolnikom, okuženim z virusom HIV, se dizoproksiltenofovirijev fumarat hitro absorbira in pretvori v tenofovir.
Following oral administration of tenofovir disoproxil fumarate to HIV infected patients, tenofovir disoproxil fumarate is rapidly absorbed and converted to tenofovir.
Pri bolnikih, okuženih s HIV, se po peroralnem vnosu dizoproksiltenofovirijev fumarat hitro absorbira in pretvori v tenofovir.
Following oral administration of Truvada to healthy subjects, emtricitabine and tenofovir disoproxil fumarate are rapidly absorbed and tenofovir disoproxil fumarate is converted to tenofovir.
Pri zdravih osebah se po peroralnem vnosu zdravila Truvada emtricitabin in dizoproksiltenofovirijev fumarat hitro absorbirata in dizoproksiltenofovirijev fumarat se pretvori v tenofovir.
Following oral administration to pregnant rabbits during the period of organogenesis, asenapine adversely affected body weight at the high dose of 15 mg.kg-1 twice daily.
Po njegovi peroralni uporabi pri brejih samicah kuncev v obdobju organogeneze je imel asenapin neugoden vpliv na telesno maso pri višjem odmerku, to je 15 mg/kg dvakrat na dan.
Following oral administration with food in HIV-1 infected patients, peak plasma concentrations were observed approximately 4 hours post-dose for elvitegravir, 3 hours post-dose for cobicistat, 3 hours post-dose for emtricitabine, and 1 hour post-dose for tenofovir alafenamide.
Po peroralnem dajanju s hrano bolnikom, okuženim z virusom HIV-1, so najvišje plazemske koncentracije opazili približno 4 ure po odmerku za elvitegravir, 3 ure po odmerku za kobicistat, 3 ure po odmerku za emtricitabin in 1 uro po odmerku za alafenamidtenofovirat.
Following oral administration, approximately 5 % to 10 % of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4- carboxamide (AIC) or unidentified polar metabolites.
Po peroralni uporabi se v 24 urah s sečem v nespremenjeni obliki izloči približno 5 % do 10 % odmerka, preostanek pa se izloči v obliki temozolomidske kisline, 5-aminoimidazol-4-karboksamida (AIC) ali neopredeljenih polarnih presnovkov.
Following oral administration, approximately 5% to 10% of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4- carboxamide (AIC) or unidentified polar metabolites.
Po peroralni uporabi se v 24 urah v nespremenjeni obliki v urin izloči približno 5 % do 10 % odmerka, preostanek pa se izloči kot temozolomidna kislina, 5-aminoimidazol-4-karboksamid (AIC) ali nedoločeni polarni presnovki.
Following oral administration, lamivudine was excreted in breast milk at similar concentrations to those found in serum.
Po peroralni uporabi se je lamivudin izločal v materino mleko v podobnih koncentracijah, kot so bile koncentracije v serumu.
Following oral administration, the elimination half-life of tenofovir is approximately 12 - 18 hours.
Po peroralni uporabi zdravila je razpolovna doba izločanja tenofovirja približno 12 do 18 ur.
Following oral administration, the increase in the mean exposure (AUC) is approximately proportional to the dose increment across doses ranging from 25 mg to 120 mg twice daily.
Po peroralnem dajanju se srednja izpostavljenost (AUC) povečuje približno sorazmerno s povečevanjem odmerka v razponu odmerkov od 25 mg do 120 mg dvakrat na dan.
Following oral administration, the mean time (tmax) to maximal serum concentrations (Cmax) is about an hour.
Po peroralnem vnosu je povprečen čas (tmax) do dosežene največje koncentracije v serumu (Cmax) približno ena ura.
Following oral administration, the mean time (tmax) to maximal serum concentrations of abacavir is about 1.5 hours for the tablet formulation and about 1.0 hour for the solution formulation.
Po peroralnem vnosu znaša povprečni čas (tmax) do največje koncentracije abakavirja v serumu približno 1,5 ure za tablete in približno 1 uro za raztopino.
Following oral and intravenous administration, levofloxacin is eliminated relatively slowly from the plasma (t1/2 6 to 8 hours).
Po peroralni in intravenski uporabi se levofloksacin relativno počasi izloča iz plazme (t1/2 : 6 do 8 ur).
Following oral dosing of 14C-olaparib to female patients, unchanged olaparib accounted for the majority of the circulating radioactivity in plasma (70%) and was the major component found in both urine and faeces (15% and 6% of the dose respectively).
Po peroralni uporabi 14C-olapariba pri bolnicah je šla večina radioaktivnosti v plazmi (70 %) na račun nespremenjenega olapariba, ki je bil tudi glavna snov v urinu in blatu (15 % odmerka v urinu in 6 % v blatu).
Following oral dosing, the absorption rate constant for the population of metastatic melanoma patients is estimated to be 0.19 hr-1 (with 101% between patient variability).
Po peroralni uporabi je ocenjena konstanta hitrosti absorpcije za populacijo bolnikov z metastatskim melanomom 0,19 h-1 (s 101-% variabilnostjo med bolniki).
Following oral or intravenous administration of 14C irbesartan, 80-85 % of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Po peroralni ali intravenski uporabi C irbesartana, prispeva 80-85 % radioaktivnosti v plazemskem obtoku nespremenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Po peroralni ali intravenski uporabi 14C irbesartana prispeva 80 do 85 % radioaktivnosti v plazemskem obtoku nespremenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Po peroralni ali intravenski uporabi 14C irbesartana, prispeva 80- 85% radioaktivnosti v plazemskem obtoku nespremenjeni irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Po peroralni ali intravenski uporabi irbesartana 14C je v obtoku 80 do 85 % nespremenjene učinkovine.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Po peroralni ali intravenski uporabi irbesartana C je v obtoku 80 do 85 % nespremenjene učinkovine.
Following oral single dose administration in the fasted state, crizotinib is absorbed with median time to achieve peak concentrations of 4 to 6 hours.
Po peroralnem zaužitju enkratnega odmerka na tešče se krizotinib absorbira z mediano časa do dosega največjih koncentracij 4 do 6 ur.
Following oromucosal administration of Effentora, fentanyl is readily absorbed with an absolute bioavailability of 65%.
Po aplikaciji zdravila Effentora prek ustne sluznice se fentanil absorbira z absolutno biološko razpoložljivostjo 65 %.
Following Overall Treatment Evaluation (OTE) of patients at week 2, 78.0-80.7% of patients on esomeprazole 20 mg, compared to 72.4 – 78.3% for placebo, reported their condition as improved.
Po skupni oceni zdravljenja po 2 tednih je 78,0–80,7 % bolnikov, ki so dobivali 20 mg esomeprazola, poročalo o izboljšanem stanju v primerjavi z 72,4–78,3 % v skupini s placebom.
Following parenteral administration of 100 I.U. calcitonin, peak plasma concentration lies between about 200 and 400 pg/ml.
Po parenteralnem dajanju 100 IE kalcitonina je maksimalna koncentracija v plazmi med 200 in 400 pg/ml.
Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio=0.78, 95 %CI=0.64- 0.96, p=0.0195).
Po indukcijskem zdravljenju pemetreksedom skupaj s cisplatinom (4 cikli) je bilo zdravljenje s pemetreksedom statistično boljše od placeba glede skupnega preživetja (mediana 13,9 mesecev v primerjavi z 11,0 meseci, razmerje tveganja = 0,78, 95 % CI=0,64-0,96, p=0,0195).
Following prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin (see section 5.1).
Po predhodnem zdravljenju z interferonom (pegiliranim ali nepegiliranim), skupaj z ribavirinom ali brez ribavirina (glejte poglavje 5.1).
Following radiolabelling, administration can be by either intradermal, subcutaneous, intratumoural, or peritumoural injection.
Po radiološki označbi se lahko uporabi za intradermalno, subkutano, intratumoralno ali peritumorno injiciranje.
Following randomization, patients from both treatment groups underwent a series of 3 leukapheresis procedures (at approximately 2 week intervals, range 1 to 15 weeks).
Po randomizaciji so imeli bolniki iz obeh skupin zdravljenja serijo 3 postopkov lefkafereze (v približno 2- tedenskih intervalih, v razponu 1 do 15 tednov).
Following recent enquiries from pharmacists and prescribers received in the past months regarding prescribing and dispensing restrictions for women of childbearing potential (WCBP), it came to the PRAC’s attention that the current warning in the Erivedge SmPC is not clear.
Po nedavnih poizvedbah glede omejitev predpisovanja in izdajanja zdravila za ženske v rodni dobi, ki smo jih v preteklih mesecih prejeli od farmacevtov in predpisovalcev, je PRAC postal pozoren, da trenutno opozorilo v povzetku glavnih značilnosti zdravila Erivedge ni jasno.
Following reconstitution and labelling, Lymphoseek is intended to be injected in close proximity to the tumour and used in preoperative gamma detection imaging in conjunction with a stationary gamma camera (scintigraphy), single photon emissioncomputed tomography (SPECT), or SPECT/computerized tomography SPECT/CT, and/or intraoperatively in conjunction with a gamma detection probe to localise sentinel lymph nodes in the lymphatic pathway draining the tumour.
Po rekonstituciji in označevanju je treba zdravilo Lymphoseek injicirati v bližini tumorja, kar mora spremljati predoperacijsko slikanje z žarki gama v kombinaciji s stacionarno kamero gama (scintigrafijo), računalniško podprto scintigrafsko tomografijo s sevalci gama (single photon emissioncomputed tomography – SPECT) ali SPECT/računalniško tomografijo SPECT/CT in/ali medoperacijsko slikanje v kombinaciji s sondo gama za določanje mesta varovalnih bezgavk v limfnem žilju, v katere odtekajo maligne celice tumorja.
Following reconstitution and radiolabelling, the material must be used within 5 hours as radiochemical purity and stability have been demonstrated for 5 hours at 25C.
Po rekonstituciji in radioaktivnem označevanju se mora raztopina uporabiti v 5 urah, ker sta bili radiokemična čistost in stabilnost dokazani za 5 ur pri 25°C.
Following reconstitution the oral suspension has a concentration of 20 mg per ml.
Po pripravi ima peroralna suspenzija koncentracijo 20 mg/ml.
Following reconstitution with the solvent (water for injections) the vial contains 1.0 ml of solution.
Po rekonstituciji z vehiklom (vodo za injekcije) vsebuje viala 1,0 ml raztopine.
Following reconstitution, unused radiopharmaceutical and vial should be handled as radioactive waste and disposed of in accordance with local requirements.
Po rekonstituciji morata biti vsa neporabljena količina radiofarmaka in viala tretirana kot radioaktivni odpadek in morata biti odstranjena v skladu z lokalnimi predpisi.
Following recovery to Grade 1 diarrhoea, resume ONIVYDE at a reduced dose (see section 4.2).
Po okrevanju do driske 1. stopnje zdravljenje z zdravilom ONIVYDE nadaljujte z zmanjšanimi odmerki (glejte poglavje 4.2).
Following reintroduction of pazopanib, if transaminase elevations > 3 x ULN recur, then pazopanib should be permanently discontinued.
Če se po ponovni uvedbi zdravljenja s pazopanibom vrednosti aminotransferaz spet zvišajo na > 3-kratno ZMN, je treba zdravljenje s pazopanibom trajno prekiniti.
Following repeat dosing of 125 micrograms doses every two weeks by subcutaneous administration, the volume of distribution uncorrected for bioavailability (mean±SE) was 481 ± 105 L.
Po ponavljajočem odmerjanju 125-mikrogramskih odmerkov vsaka dva tedna po subkutani poti je bil volumen porazdelitve brez korekcije za biološko uporabnost (povprečje ± SN) 481 ± 105 l.
Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (up to three-fold as measured by AUC(0–24)) in subjects with hepatic impairment (Child-Pugh A, B or C) compared with healthy subjects.
Po ponavljajočem se odmerjanju flutikazonfuroata/vilanterola 7 dni se je sistemska izpostavljenost flutikazonfuroatu pri preiskovancih z okvaro jeter (Child-Pugh A, B in C) povečala (do trikrat, merjeno z AUC(0-24)) v primerjavi z zdravimi preiskovanci.
Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was no significant increase in systemic exposure to vilanterol (Cmax and AUC) in subjects with mild, moderate, or severe hepatic impairment (Child-Pugh A, B or C).
Po ponavljajočem se odmerjanju flutikazonfuroata/vilanterola 7 dni se sistemska izpostavljenost vilanterolu (Cmax in AUC) pri preiskovancih z blago, zmerno ali hudo okvaro jeter (Child-Pugh A, B ali C) ni bistveno povečala.
Following repeat dosing of orally inhaled fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (on average two-fold as measured by AUC(0–24)) in subjects with moderate or severe hepatic impairment (Child-Pugh B or C) compared with healthy subjects.
Po ponavljajočem se odmerjanju peroralno inhalirane kombinacije flutikazonfuroat/vilanterol v obdobju 7 dni se je sistemska izpostavljenost flutikazonfuroata pri preiskovancih z zmerno ali hudo okvaro jeter (Child-Pugh B ali C) v primerjavi z zdravimi preiskovanci povečala ( v povprečju za dvakrat, merjeno z AUC(0-24)).
Following repeated administration, follitropin alfa accumulates 3-fold achieving a steadystate within 3-4 days.
Po večkratnem dajanju doseže folitropin alfa trikratno raven v plazmi, stanje dinamičnega ravnovesja pa v 3 do 4 dneh.
Following repeated doses of NUEDEXTA 23 mg / 9 mg and NUEDEXTA 15 mg / 9 mg, maximal plasma concentrations (Cmax) of dextromethorphan are reached approximately 3 to 4 hours after dosing and maximal plasma concentrations of quinidine are reached approximately 2 hours after dosing.
Po večkratnih odmerkih zdravila NUEDEXTA 23 mg/9 mg in NUEDEXTA 15 mg/9 mg so najvišje plazemske koncentracije (Cmax.) dekstrometorfana dosežene približno 3 do 4 ure po odmerjanju, najvišje plazemske koncentracije kinidina pa približno 2 uri po odmerjanju.
Following repeated dosing of eliglustat 84 mg twice daily, steady state was reached by 4 days, with an accumulation ratio of 3-fold or less.
Po ponavljajočih odmerkih eliglustata 84 mg dvakrat dnevno so dinamično ravnovesje dosegli v štirih dneh s trikratnim akumulacijskim razmerjem ali manjšim.
Following repeated topical application of the ointment the average half-life of tacrolimus was estimated to be 75 hours for adults and 65 hours for children.
Po večkratni lokalni uporabi mazila je bil ocenjeni povprečni razpolovni čas takrolimusa pri odraslih 75 ur in pri otrocih 65 ur.
Following resolution of transaminase elevations, the benefits and risks of resuming Kalydeco dosing should be considered.
Ko zvišanje transaminaz izzveni, je treba pretehtati koristi in tveganja ponovnega začetka odmerjanja zdravila Kalydeco.
Following SC administration, bioavailability was 62%.
Po subkutani uporabi je bila biološka uporabnost 62 %.
Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %).
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), ≥ 15 % (pogosto) in pogosto ≥ 25 % občasno (0,8 %).
Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %).
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), ≥ 15 % pogosto (4,2 %) in za ≥ 25 % občasno (0,8 %).
Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %).
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), za ≥ 15 % pogosto (4,2 %) in za ≥ 25 % občasno (0,8 %).
Following single dose Combivir administration in healthy volunteers, mean (CV) lamivudine and zidovudine Cmax values were 1.6 µg/ml (32%) and 2.0 µg/ml (40%), respectively and the corresponding values for AUC were 6.1 µg h/ml (20%) and 2.4 µg h/ml (29%) respectively.
Po zaužitju enkratnega odmerka zdravila Combivir so pri zdravih prostovoljcih srednje (CV) vrednosti Cmax lamivudina znašale 1,6 μg/ml (32 %) in zidovudina 2,0 μg/ml (40 %), pripadajoče vrednosti površine pod krivuljo (AUC) pa so bile 6,1 μg h/ml (20 %) oziroma 2,4 μg h/ml (29 %).